Jan 13, 2025 8:00am EST Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Dec 19, 2024 7:30am EST Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Dec 02, 2024 4:00pm EST First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
Nov 05, 2024 9:19am EST Adaptimmune to Participate in Scientific and Medical Conferences this November and December
Oct 31, 2024 5:20pm EDT Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
Aug 05, 2024 8:00am EDT Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024
